Figure 6
From: Differential prognostic values of the three AKT isoforms in acute myeloid leukemia
Expression of each AKT transcript as a function of SRF2, U2AF1, SF3B1, ASXL1 or BCOR mutations and of prior MDS or prior MPN hematological disorders. Each dot shows expression (log2 RPKM) of each AKT as a function of SRSF2 (n = 46), U2AF1 (n = 24), SF3B1 (n = 17), ASXL1 (n = 43) or BCOR (n = 23) mutations in 445 samples of the Beat-AML cohort (“wt” means no mutation in any of these 5 genes) (left), or in 445 samples but classified according to whether or not patients developed a MDS (n = 32), a MPN (n = 18) or a combination of both (n = 12) before the onset of leukemia (right). Bars represent medians with 95% CI. Student t tests were here calculated after having grouped mutant (left) or MDS + MPN + both (right) samples.
